제2회 서울국제신약포럼 > Forum & Conference

본문 바로가기

파이낸셜뉴스 부산파이낸셜뉴스 블록포스트 가이드포스트 fn아이포커스 파이낸셜뉴스재팬 fnMICE fn이노에듀 fn투어


지난행사목록

본문

 

Choung-Un Kim
Vice President Chemistry/Gilead Sciences



HARVARD UNIVERSITY, 1971 to 1973, Post Doctoral Fellow
Professor Elias J. Corey,
Total Synthesis of Prostaglandin A2 and New Oxidation Reaction
Using Sulfide-Halogen Complex

UNIVERSITY OF ALBERTA, 1970 to 1971, Post Doctoral Fellow
Professor S. Masamune,
Total Synthesis of Methymycin

UNIVERSITY OF OREGON, 1967 to 1970, Ph.D. in Organic Chemistry
John F. W. Keana,
Studies Directed Toward the Total Synthesis of Tetrodotoxin and Derivatives

UNIVERSITY OF TOKYO, 1965 to 1967, M.S. in Organic Chemistry
Professor Fukunaga
Synthesis of Bridged Aromatic Compounds

UNIVERSITY OF TOKYO, 1961 to 1965, B.S. in Pharmaceutical Sciences



1999 - Present Vice President, Chemistry
Gilead Sciences, Foster City, CA

1997 - 1999 Senior Director, Medicinal Chemistry
Gilead Sciences, Foster City, CA

1994 - 1997 Director, Medicinal Chemistry
Gilead Sciences, Foster City, CA

1991 - 1994 Senior Principal Scientist in Medicinal Chemistry
Bristol-Myers Squibb, Wallingford, CT

1984 - 1991 Research Fellow in Antiinfective Chemistry
Bristol-Myers Squibb, Wallingford, CT

1973 - 1984 Senior Research Chemist in Medicinal Chemical Research
Bristol Laboratories, Division of Bristol-Myers Company


2009 ACS E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances
2009 KASBP Achievement Award for Discovery of Anti-influenza drug “Tamiflu”
 
 
Moon-Hwan Kim, Ph.D.
Director, Medicinal Chemistry/Exelixis Inc.


Postdoctoral Fellowship at SUNY Buffalo
Postdoctoral Fellowship at Memorial Sloan-Kettering Cancer Center, NY
Ph.D. at Seoul National University, Medicinal Chemistry
MS at Seoul National University, Medicinal Chemistry
BS at Yeoungnam University, Pharmaceutical Science


Present: Exelixis Inc. South San Francisco, CA, Director in Medicinal Chemistry
Affymax Research Institute, Santa Clara, CA, Staff Scientist
NIH Proposal Reviewer
 
 
Alex Matter, M.D.
Chairman, Esperanza Medicines Foundation, Basel, Switzerland/CEO, Experimental Therapeutics Centre, A*STAR, Singapore

Professor Alex Matter, M.D., is CEO of the Experimental Therapeutics Centre, A*STAR, Singapore, having spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation, Head of Novartis Institutes for BioMedical Research in Basel and Global Head of Translational Research. Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec and more recently, Tasigna, building and leading the teams that discovered these and several other anticancer drugs as well as one HIV protease inhibitor (Reyataz) that is marketed by another company. 

Dr. Matter received his medical degree from the University of Basel. He also had fellowships at the Swiss National Science Foundation and the Swiss Academy for Medical Sciences. He has published more than 100 scientific articles and several book chapters in the area of oncology and hematology. He is emeritus Professor of the Medical Faculty of the University Basel and an Honorary Adjunct Professor of the Department of Pharmacology, YLL School of Medicine, NUS in Singapore.

He is a member of the American Association for Cancer Research, the National Medical Research Council in Singapore, and the Board of Curiox, a Singapore-based start up company. He is also a member of several Scientific Advisory Boards. He is an elected member of the Swiss Academy of Medical Sciences.

Dr. Matter is the recipient of the Life-time Achievement Award from IBC Life Sciences, the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award. 

In 2004, he co-founded Esperanza Medicines Foundation and is currently its Chairman. This foundation has as its mission to develop affordable anti-HIV/AIDS drugs for developing countries based on Natural Products.
 
 
Su-Youn Nam, MD. PhD.
Executive Director, R&D/Yuhan Corporation

Dr. Nam received her MD and PhD in Internal Medicine/Endocrinology from the Yonsei University in Seoul, Korea, and went on to be Assistant Professor in Endocrinology at the same institution. Following a postdoc research at the Karolinska Institute in Stockholm, Sweden, she joined the pharmaceutical industry, initially as Medical Director at Roche in Korea. She moved on to BMS in 2004 as Medical Director in Korea, followed by assignments as Asia-Pacific Regional Medical Lead in Cardiovascular & Metabolics area based in Singapore, and as Global Medical Director in the Metabolics Franchise of Global Medical Affairs, Princeton, NJ where she developed and executed global medical strategies. Then she moved to Discovery Medicine space to head up early clinical programs in cardiovascular & metabolics pipeline. Recently she came back to Korea and is currently leading the R & D effort at Yuhan Corporation, Korea. 
Dr. Nam has a strong background in Endocrinology and Metabolism, both from a clinical and basic research perspective, which is reflected in her publication history and an impressive list of awards. She has been working in a full dimension of R & D from early clinical development strategy to life cycle management programs in addition to her robust experiences in regional clinical development.
 
 
Young-Choon Moon
Director, Chemistry/PTC Therapeutics Inc.

1976 – 1980 Sogang University, B.S. Chemistry & Trade 
1980 – 1982 Korea Advanced Institute of Science & Technology, M.S. Organic Chemistry 
1985 – 1990 University of Illinois, Urbana-Champaign, Ph.D. Organic Chemistry 
1990 – 1993 Harvard University, Postdoctoral Research Associate 
1996 – 1997 University of California at Berkeley, Visiting Scholar

2002 – 2003 Group Leader, Combinatorial Chemistry, PTC Therapeutics, Inc. 
2003 – 2006 Group Leader, Analytical Chemistry, PTC Therapeutics, Inc.
2002 – Associate Director of Chemistry, PTC Therapeutics, Inc.
2007 – Director of Chemistry, PTC Therapeutics, Inc.


PTC124: Co-inventor of PTC124, Developer of Process Chemistry
Human Clinical Trial Ph IIb/III in Duchenne Muscular Dystrophy and Cystic Fibrosis Research Currently in Process
PTC299: Project Leader and Inventor of PTC124, Developer of Process Chemistry
Human Clinical Trial Ph Ib/III in Metastatic Breast Cancer, Advanced Cancer, and HIV-Related Kaposi's Sarcoma Research Currently in Process


Excellence Prize, Sogang University Research Paper (1978)
Encouragement Prize, Seoul National University Research Presentation.(1978)
University of Illinois R. C. Fuson Travel Award (1988)
SBR/CKD Bioscience Award, 14th Annual Meeting of Society of Biomedical Research (2004)
KASBP-Daewoong Year of Scientist Award, 8th Annual KASBP Symposium (2008)


1979 – 1980 Alpha Sigma Nu Honor Society, Sogang University,
1980 – Alpha Sigma Nu Honor Society, Sogang Alumni
1985 – American Chemical Society, Organic Chemistry and Medicinal Chemistry Division
1998 – Society of Biomedical Research
2002 – Korean-American Society in Biotech & Pharmaceutical Industries (KASBP)
2003 – Korean-American Scientists and Engineers Association (KSEA)
American Association for Cancer Research
 
 
Gio-Bin Lim
General Director, Next Generation Growth Engine/Korea Biotech R&D Group


1978 B.S., Chemical Engineering, Yonsei University
1982 M.S., Chemical Engineering, Yonsei University
1989 Ph.D., Chemical Engineering, University of Pittsburgh
1989 – 1990 Post Doc., Food Science, Cornell University
1990 – 1991 Post Doc., Chemical Engineering, Princeton University
1991 – Professor, Chemical Engineering, University of Suwon
2005 – 2006 Project Manager (PM), Korea Research Foundation (KRF), Ministry of Education, Science and Technology (MEST)
2006 – 2007 Chief Project Manager and PM in Biotechnology, Korea Institute of Industrial Technology Evaluation and Planning (ITEP), Ministry of Knowledge Economy (MKE)
2007 – General Director, Next Generation Growth Engine, Korea Biotech R&D Group (KBRDG), MEST
2009 – President, Korea Drug Researcher Association, MEST
2009 Chief Vice President, Korean Society of Biotechnology and Bioengineering 2010 – President, Korean Society of Biotechnology and Bioengineering

Award
2005 The 15th Excellent Science and Technology Research Award, Korean Federation of Sci. and Tech. Societies (KOFST), MEST
 
 
Jun-Ho Chung M.D., Ph.D.
Professor & Chairman, Department of Biochemistry and Molecular Biology/Seoul National University School of Medicine & Cancer Research Institute, Seoul National University


1988 Medicine M.D, Seoul National University
1990 Biochemistry M.S, Seoul National University 
1994 Biochemistry Ph. D, Seoul National University
1999- 2000 Research Associate, Molecular Biology, The Scripps Research Institute. 


1992-1994 Full-time Instructor, Department of Biochemistry, Dong-guk University College of Medicine (in Korea)
1994-1997 Physician as a substitute of military position (the mandatory duty for every Korean male doctor), Department of Health Science, Pohang Christian Hospital
1997-1999 Assistant Professor, Department of Biochemistry, Dong-guk University College of Medicine (in Korea)
1999-2000 Research Associate, Department of Molecular Biology, The Scripps Research Institute
2000-2002 Assistant Professor, Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine (in Korea)
2000- 2003 Principal Investigator (as a dual appointment), Division of Molecular Oncology, Department of Basic Sciences, National Cancer Center Research Institute (in Korea)
2002-Present Associate Professor, Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine (in Korea)


President, Korean Society for Antibody Engineering. (2007 – 2009)
Vice president, Korean Society for Antibody Engineering. (2002 – 2007)
Executive member, Korean Society for Molecular and Cellular Biology
 
 

첨부파일

서울특별시 서초구 강남대로 315, 파이낸셜뉴스빌딩 9층 | TEL. 02-6965-0016 | FAX. 02-6965-0000 | E-mail : info@fnmice.com
Copyright (c) fnMICE. All rights reserved.